-

Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.

Dr. Roland Green, CEO of Invenra, remarks, “We are excited to collaborate with the innovative team at Catalent’s Redwood Bioscience subsidiary. We believe that the combination of Invenra’s B-Body bispecific antibody platform with Catalent's SMARTag® ADC expertise has the potential to unlock synergies and accelerate the development of next-generation cancer therapeutics.”

Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.

About Invenra Inc:

Driven by our mission to deliver groundbreaking therapies to patients worldwide and a commitment to innovation and excellence, Invenra is a leading bispecific antibody technology company. Our proprietary B-Body® platform offers profound advantages in discovery, manufacturing, and formulation, along with true "Plug & Play" performance, enabling rapid engineering of therapeutics. Our extensive portfolio of wholly owned and partnered molecules includes first and best-in-class bispecifics, making us a pioneer in therapeutic innovation.

Contacts

Invenra Media Contact
Bryan Glaser
Senior Vice President Business Development
Invenra Inc.
608-441-8319
bglaser@invenra.com

Industry:

Invenra Inc.

Release Versions
English

Contacts

Invenra Media Contact
Bryan Glaser
Senior Vice President Business Development
Invenra Inc.
608-441-8319
bglaser@invenra.com

More News From Invenra Inc.

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development

MADISON, Wis, & NORTH BETHESDA, Md.--(BUSINESS WIRE)--Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs. Under the collaboration, Invenr...

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

MADISON, Wis.--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a...

Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (...
Back to Newsroom